White Paper: EMA’s 2017 FIH Guidelines. 5 years on and the Impact on Early Phase Clinical Studies
AC-Impact-of-EMAs-guidelines-on-FIH-studies-2022-White-Paper-Download
Continuing Non-Clinical Evidence Generation Throughout Drug Development:
Important goals of pre-clinical drug development programs (in silico, in vivo, in vitro studies) include the formulation of precise estimates…